Research view
Switch to patient viewGastric and oesophageal cancer: trials that stopped early
Trials on Gastric and oesophageal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
131 stopped trials give a reason in the registry, latest registry update first. 5 more give no reason and are not listed.
Terminated
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Reason given in the registry “Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment in another study.”
Quoted unchanged from ClinicalTrials.gov; record updated 5 May 2026.
- Ended
- Sept 2024
- Phase
- Phase 2
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT04034251
Suspended
Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)
Reason given in the registry “Pending Protocol amendment”
Quoted unchanged from ClinicalTrials.gov; record updated 4 May 2026.
- Run by
- Rutgers, The State University of New Jersey
- Registry record
- NCT04929015
Terminated
A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Reason given in the registry “Patient recruitment problems.”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Apr 2026.
- Ended
- Dec 2025
- Phase
- Phase 1/2
- Run by
- Aurigene Discovery Technologies Limited
- Registry record
- NCT07040059
Terminated
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
Reason given in the registry “Patient recruitment problems”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Apr 2026.
- Ended
- Feb 2026
- Phase
- Phase 1
- Run by
- Aurigene Discovery Technologies Limited
- Registry record
- NCT05861947
Terminated
Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer
Reason given in the registry “PI leaving institution”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Apr 2026.
- Ended
- Jun 2025
- Run by
- The University of Texas Health Science Center at San Antonio
- Registry record
- NCT04600466
Terminated
A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer
Reason given in the registry “Since activation, 3 subjects were enrolled but were ineligible for randomization to a treatment arm because of a positive diagnostic laparoscopy result. Given the repeat inability to enroll and randomize an eligible subject; accrual was halted.”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Apr 2026.
- Ended
- Feb 2025
- Phase
- Phase 2
- Run by
- Baylor College of Medicine
- Registry record
- NCT05567835
Suspended
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
Reason given in the registry “Sponsor has decided to permanently close recruitment”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Apr 2026.
- Ended
- Oct 2026
- Phase
- Phase 1/2
- Run by
- Cancer Research UK
- Registry record
- NCT04908111
Terminated
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Reason given in the registry “Business Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Apr 2026.
- Ended
- Aug 2024
- Phase
- Phase 1
- Run by
- Conjupro Biotherapeutics, Inc.
- Registry record
- NCT04931823
Suspended
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Reason given in the registry “Pending data analysis”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Mar 2026.
- Ended
- Jun 2026
- Phase
- Phase 4
- Run by
- University of Chicago
- Registry record
- NCT02366819
Terminated
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Reason given in the registry “Due to lack of efficacy shown at the time of the interim analysis.”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Mar 2026.
- Ended
- Nov 2024
- Phase
- Phase 1
- Run by
- SOTIO Biotech AG
- Registry record
- NCT04234113
Terminated
A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group
Reason given in the registry “Due to the extension of the clinical trial period due to a problem that occurred in the first patient of this study, there were concerns about business viability, so we decided to cancel this study.”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Mar 2026.
- Ended
- Dec 2023
- Phase
- Phase 3
- Run by
- CellSeed Inc.
- Registry record
- NCT04689594
Withdrawn
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Reason given in the registry “Strategic development reasons”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Feb 2026.
- Ended
- Jun 2026
- Phase
- Phase 1/2
- Run by
- Institut de Recherches Internationales Servier
- Registry record
- NCT05312372
Terminated
The PLATON Network
Reason given in the registry “Sponsor Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Feb 2026.
- Ended
- Jun 2025
- Run by
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Registry record
- NCT05489250
Terminated
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Reason given in the registry “Clinical Futility of TAK 500 met. No further development with this compound”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Jan 2026.
- Ended
- Jan 2025
- Phase
- Phase 1/2
- Run by
- Takeda
- Registry record
- NCT05070247
Terminated
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Reason given in the registry “Business Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Jan 2026.
- Ended
- Nov 2025
- Phase
- Phase 1/2
- Run by
- Ocellaris Pharma, Inc.
- Registry record
- NCT04260802
Withdrawn
Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma
Reason given in the registry “The pharmaceutical company is not moving forward with this intervention due to lack of efficacy.”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Dec 2025.
- Phase
- Phase 2
- Run by
- Massachusetts General Hospital
- Registry record
- NCT07283848
Terminated
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
Reason given in the registry “The decision was not based on any safety concerns”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Dec 2025.
- Ended
- Dec 2024
- Phase
- Phase 1
- Run by
- Novartis Pharmaceuticals
- Registry record
- NCT05977322
Terminated
Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer
Reason given in the registry “default inclusion”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Dec 2025.
- Ended
- Aug 2024
- Phase
- Phase 3
- Run by
- University Hospital, Lille
- Registry record
- NCT03042169
Terminated
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Reason given in the registry “The trial was stopped early on the initiative of the sponsor on the basis of a change in the research and development strategy without safety concerns”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Dec 2025.
- Ended
- Jan 2024
- Phase
- Phase 1
- Run by
- Shanghai Junshi Bioscience Co., Ltd.
- Registry record
- NCT05427396
Terminated
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Reason given in the registry “Business Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Nov 2025.
- Ended
- Jun 2025
- Phase
- Phase 1
- Run by
- Elevation Oncology
- Registry record
- NCT05980416
Terminated
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Reason given in the registry “Recruitment challenges”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Oct 2025.
- Ended
- Aug 2024
- Phase
- Phase 2
- Run by
- Tempus AI
- Registry record
- NCT05169437
Terminated
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Reason given in the registry “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2025.
- Ended
- Aug 2024
- Phase
- Phase 1
- Run by
- Incyte Corporation
- Registry record
- NCT04272034
Terminated
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Reason given in the registry “Sponsor's strategic business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2025.
- Ended
- Aug 2025
- Phase
- Phase 1
- Run by
- Actym Therapeutics, Inc.
- Registry record
- NCT06336148
Terminated
Futibatinib in Patients With Specific FGFR Aberrations
Reason given in the registry “Sponsor made a strategic decision to terminate the study considering enrollment challenges for some of the cohorts in the trial.”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Oct 2025.
- Ended
- Nov 2024
- Phase
- Phase 2
- Run by
- Taiho Oncology, Inc.
- Registry record
- NCT04189445
Terminated
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
Reason given in the registry “This study was terminated as a result of Sponsor portfolio reprioritization.”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Sept 2025.
- Ended
- Apr 2025
- Phase
- Phase 1
- Run by
- NiKang Therapeutics, Inc.
- Registry record
- NCT06264921
Terminated
NIF-Guided RAMIE Using ICG Versus OTE Feasibility RCT
Reason given in the registry “The study was closed due to adverse events because the adverse event rate was not lower than the adverse event rate in traditional open esophagectomy.”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Sept 2025.
- Ended
- Jun 2025
- Run by
- St. Joseph's Healthcare Hamilton
- Registry record
- NCT04938973
Terminated
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Reason given in the registry “Sponsor Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Sept 2025.
- Ended
- Feb 2025
- Phase
- Phase 1/2
- Run by
- Bolt Biotherapeutics, Inc.
- Registry record
- NCT04278144
Withdrawn
Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
Reason given in the registry “The primary reason for termination was difficulty in recruitment”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Aug 2025.
- Run by
- Hebei Medical University Fourth Hospital
- Registry record
- NCT06420908
Terminated
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Reason given in the registry “Sponsor reprioritization of active trials.”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Aug 2025.
- Ended
- Feb 2025
- Phase
- Phase 1
- Run by
- 3B Pharmaceuticals GmbH
- Registry record
- NCT05605522
Terminated
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
Reason given in the registry “Sponsor decision, the decision is not related to any safety concern.”
Quoted unchanged from ClinicalTrials.gov; record updated 22 Aug 2025.
- Ended
- Nov 2024
- Phase
- Phase 2
- Run by
- Sanofi
- Registry record
- NCT05071053
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.